Next Article in Journal
Two Indicators of Hospital Resource Efficiency in Cancer Care
Previous Article in Journal
Effect of Preoperative Chemoradiotherapy on Outcome of Patients with Locally Advanced Esophagogastric Junction Adenocarcinoma—A Pilot Study
 
 
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Cancer and Venous Thromboembolic Disease: From Molecular Mechanisms to Clinical Management

1
Department of Hematology, Mater Misericordiae University Hospital, Dublin 6, Ireland
2
Department of Medical Oncology, Bon Secours Hospital, Cork, Ireland
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2014, 21(3), 134-143; https://doi.org/10.3747/co.21.1864
Submission received: 4 March 2014 / Revised: 9 April 2014 / Accepted: 8 May 2014 / Published: 1 June 2014

Abstract

Venous thromboembolism (VTE) represents a major challenge in the management of patients with cancer. The malignant phenotype is associated with derangements in the coagulation cascade that can manifest as thrombosis, hemorrhage, or disseminated intravascular coagulation. The risk of VTE is increased by a factor of approximately 6 in patients with cancer compared with non-cancer patients, and cancer patients account for approximately 20% of all newly diagnosed cases of VTE. Postmortem studies have demonstrated rates of VTE in patients with cancer to be as high as 50%. Despite that prevalence, VTE prophylaxis is underused in hospitalized patients with cancer. Studies have demonstrated that hospitalized patients with cancer are less likely than their non-cancer counterparts to receive VTE prophylaxis. Consensus guidelines address the aforementioned issues and emerging concepts in the area, including the use of risk-assessment models, biomarkers to identify patients at highest risk of VTE, and use of anticoagulants as anticancer therapy. Despite those guidelines, a gulf exists between current recommendations and clinical practice; greater efforts are thus required to ensure effective implementation of strategies to reduce the incidence of VTE in patients with cancer.
Keywords: venous thromboembolism venous thromboembolism

Share and Cite

MDPI and ACS Style

Donnellan, E.; Kevane, B.; Bird, B.R.H.; Ni Ainle, F. Cancer and Venous Thromboembolic Disease: From Molecular Mechanisms to Clinical Management. Curr. Oncol. 2014, 21, 134-143. https://doi.org/10.3747/co.21.1864

AMA Style

Donnellan E, Kevane B, Bird BRH, Ni Ainle F. Cancer and Venous Thromboembolic Disease: From Molecular Mechanisms to Clinical Management. Current Oncology. 2014; 21(3):134-143. https://doi.org/10.3747/co.21.1864

Chicago/Turabian Style

Donnellan, E., B. Kevane, B.R. Healey Bird, and F. Ni Ainle. 2014. "Cancer and Venous Thromboembolic Disease: From Molecular Mechanisms to Clinical Management" Current Oncology 21, no. 3: 134-143. https://doi.org/10.3747/co.21.1864

APA Style

Donnellan, E., Kevane, B., Bird, B. R. H., & Ni Ainle, F. (2014). Cancer and Venous Thromboembolic Disease: From Molecular Mechanisms to Clinical Management. Current Oncology, 21(3), 134-143. https://doi.org/10.3747/co.21.1864

Article Metrics

Back to TopTop